TerminatedNot Applicable

Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product.

Stopped: Business Reasons

United States3 participantsStarted 2021-09-29

Plain-language summary

A long-term follow-up study to assess safety and efficacy in patients previously treated with Mustang Bio chimeric antigen receptor (CAR)-T cell investigational products.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients previously treated with a Mustang Bio CAR-T cell investigational product in a prior Mustang Bio sponsored clinical study. * Patient has provided signed and dated informed consent. Exclusion Criteria: * None. All patients who have received prior treatment with Mustang Bio CAR-T cell investigational product in a Mustang Bio sponsored clinical study are eligible for this long-term follow up (LTFU) study.

What they're measuring

Adverse events (AEs)

Timeframe: Up to a total of 15 years

Replication competent lentivirus (RCL)

Timeframe: Up to a total of 15 years

Trial details

NCT IDNCT05645744

SponsorMustang Bio

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2024-04-12

View on ClinicalTrials.gov More Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) trials